Antirheumatic effect of pirfenidone in a double blind clinical pilot trial in humans

Research Communications in Molecular Pathology and Pharmacology

Volumn 115-116, Issue , 2004, Pages 39-48

  Pesce, E ^a   Struma, E ^a   Giri, S N ^b   Margolin, S B ^c  

^a Local Health Unit   (Italy)

^b Solanan Inc   (United States)

^c Marnac Inc   (United States)

Author keywords

Pirfenidone; Rheumatoid arthritis; TNF

Indexed keywords

OXYPHENBUTAZONE; PIRFENIDONE; ANTIRHEUMATIC AGENT; PYRIDONE DERIVATIVE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; RHEUMATIC DISEASE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT; RHEUMATOID ARTHRITIS;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OXYPHENBUTAZONE; PATIENT DROPOUTS; PILOT PROJECTS; PYRIDONES; TREATMENT OUTCOME;

EID: 34447282447     PISSN: 10780297     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Al-Bayati, M.A., Xie, Y., Mohr, F.C., Margolin, S.B., and Giri, S.N. (2002). Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. Biochem. Pharmacol. 64: 517-525.
2. Armendariz-Borunda, J., Islas-Carbajal, M.C., Meza, E., Rincon, A.R., Alvarez, A., Goodman, Z.D., Sandoval, A.S., Covarrubias, A., Menchaha, J.I., Arechiga, G., and Garcia, L., (2003). A pilot study of a novel anti-inflammatory and antifibrotic agent, pirfenidone, in patients with liver Cirrhosis. Hepatology. AASLD Abstract 314: 308A.
3. Arend, W.P., and Dayer, J.M. (1995). Inhibition of the production and effects of Interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum. 38: 151-160.
4. Bathon, J.M., Martin, R.W., Fleischmann, R.M., Tesser, J.R., Schiff, M.H., Keystone, E.C., Genovese, M.C., Wasko, M.C., Moreland, L.W., Weaver, A.L., Markenson, J., and Finck, B.K. (2000). A comparison of entanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343: 1586-1593.
5. Brennan, F.M., Maini, R.N. and Feldmann, M. (1998). Role of proinflammatory cytokines in rheumatoid arthritis. Springer Immunol. 20: 133-147.
6. Cain, W.C., Stuart, R.W., Lefkowitz, D.L., Starnes, J.D., Margolin, S.B., and Lefkowitz, S.S. (1998). Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Intl. J. Immunol. 20: 685-695.
7. Dahl, S.L., Samuelson, C.O., Williams, H.J., Ward, J.R., and Karg, M. (1990). Second-line antirheumatic drugs in the elderly with rheumatoid arthritis: a post hoc analysis of three controlled trails. Pharmacotherapy 10: 79-84.
8. Feldmann, M., Brennan, F.M., Elliott, M., Katsikis, P., and Maini, R.N. (1994). TNF alpha as a therapeutic target in rheumatoid arthritis. Circ. Shock. 43: 179-184.
9. Gahl, W.A., Brantly, M., Troendle, J., Avila, N.A., Padua, A., Montalvo, C., Cardona, H., Calis, K.A., and Gochuico, B. (2002). Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol. Genet. Metab. 76: 234-242.
10. Gurujeyalakshimi, G., Hollinger, M.A., and Giri, S.N. (1999). Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am. Physiol. Soc. 276 (Lung Cell Mol. Physiol). 20: L311-L318.
11. Iyer, S.N., Hyde, D.M., and Giri, S.N. (2000). Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. 24: 477-491.
12. Iyer, S.N., Wild, J.S., Schiedt, M.J., Hyde, D.M., Margolin, S.B. and Giri, S.N. (1995). Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J. Lab Clin. Med. 125: 779-785.
13. Iyer, S.N., Gurujeyalakshimi, G., and Giri, S.N. (1999). Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 291: 367-373.
14. Iyer, S.N., Du, X., Norris, C., Margolin, S.B., and Giri, S.N. (2003). Effects of pirfenidone on inflammatory cytokines, CD4 and CD8 T-cells and nitric oxide levels in the bronchoalveolar lavage fluid in bleomycin mouse model of pulmonary fibrosis. Am. J. of Respir. Crit. Care Med. 167: 621A.
15. Kaneko, M., Inoue, H., Nakazawa, R., Azuma, N., Suzuki, M., Yamauchi, S., Margolin, S.B., Tsubota, K., and Saito, I. (1998). Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin. Exp. Immunol. 113: 72-76.
16. Kavanaugh, A.F. (1997). Rheumatoid arthritis in the elderly: is it a different disease? Am. J. Med. 103: 40S-48S.
17. Kehrer, J.P., and Margolin, S.B. (1997). Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol. Lett. 90: 125-132.
18. Lawrence, R.C., Helmick, C.G., Arnett, F.C., Deyo, R.A., Felson, D.T., Giannini, E.H., Heyse, S.P., Hirsch, R., Hochberg, M.C., Hunder, G.G., Liang, M.H., Pillemer, S.R., Steen, V.D., and Wolfe, F. (1998). Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 41: 778-799.
19. Lee, B.S., Margolin, S.B., and Nowak, R.A. (1998). A novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J. Clin. Endocrinol. Metab. 83: 219-223.
20. Lindor, N.M., Dozois, R., Nelson, H. Wolff, B., King, J., Boardman, L., Wilson, M., Greene, M.H., Karnes, Jr., W., Mesa, R., Welch, T., Edmonson, J, and Limburg, P. (2003). Desmoid tumors in familial adenomatous polyposis: A pilot project evaluating efficacy of treatment with pirfenidone. Am. J. Gastroenterol. 98: 1868-1874.
21. Lipsky, P.E., van der Heijde, D.M., St. Clair, E.W., Furst, D.E., Breedveld, F.C., Kalden, J.R., Smolen, J.S., Weisman, M., Emery, P., Feldmann, M., Harriman, G.R., and Maini, R.N. (2000). Infliximab and methrotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N. Engl. J. Med. 343: 1594-1602.
22. Lurton, J.M., Margolin, S.B., and Raghu, G. (1996). Pirfenidone inhibits the stimulatory effects of pro-fibrotic cytokines on human fibroblasts in vitro. Am. J. Respir. Crit. Care Med. 153: A403.
23. Matteson, E.L. (2001). Rheumatoid arthritis: Treatment In: Primer on the rheumatic diseases. Edited by Klippel, J.H., Crofford, L.J., Stone, J.H., and Weyand, C.M., Arthritis Foundation., Atlanta, GA, 225-231.
24. Mitchell, D. (1985). Epidemiology. In: Utsinger, P.D., Zvaifler, N.J., Ehrlich, G.E., editors. Rheumatoid arthritis: etiology, diagnosis, management. Philadelphia: J.B. Lippincott. 133-137.
25. Moreland, L.W., Baumgartner, S.W., Schiff, M.H., Tindall, E.A., Fleischmann, R.M., Weaver, A.L., Ettlinger, R.E., Cohen, S., Koopman, W.J., Mohler, K., Widmer, M.B., and Blosch, C.M. (1997). Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Eng. J. Med. 337: 141-147.
26. Muller-Lander, U. (1996). Molecular and cellular interactions in rheumatoid synovium. Curr. Opin. Rheumatol. 8: 210.
27. Raghu, G., Johnson, W.C., Lockhart, D., Mageto, Y.C. (1999). Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Results of a prospective, open-label Phase II study. Am. J. Respir. Crit. Care Med. 159: 1061-1069.
28. Rosenberg, A. (1999). Bones, joints, and soft tissue tumors. In: Robbins Pathologic Basis of Disease. Edited by Cotran, R.S., Kumar, V., and Tucker, C. W.B. Saunders Co., N.Y., U.S.A. 1246-1252.
29. th Edition. McGraw-Hill, New York. 1649-1677.
30. Tada, S., Nakamuta, M., Enjoji, M., Sugimoto, R., Iwamoto, H., Kato, M., Nakashima, Y, and Nawata, H. (2001). Pirfenidone inhibits dimethylnitrosamine- induced hepatic fibrosis in rats. Clin. Exp. Pharmacol. Physiol. 28: 522-527
31. Weinblatt, M.E. (1991). Nonsteroidal anti-inflammatory drug toxicity: increased risk in the elderly. Scand J. Rheumatol. Suppl. 91: 9-17.
32. Weinblatt, M.E., Kremer, J.M., Bankhurst, A.D., Bulpitt, K.J., Fleischmann, R.M., Fox, R.I., Jackson, C.G., Lange, M., and Burge, D.J. (1999). A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340: 253-259.